Haematologica

Haematologica www.haematologica.org publishes novel findings in basic, clinical and translational hematology research. Impact Factor (JCR) 7.116 (7th of 76)

Haematologica/The Hematology Journal (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by a non-profit organization, the Ferrata Storti Foundation, and serves the scientific community strictly following the International Committee of Medical Journal Editors (ICMJE, www.icmje.org) recom

mendations on publication ethics policies for medical journals. Haematologica was founded in 1920 by Adolfo Ferrata

Review series on clonal hematopoiesis: what drives its progression to myeloid neoplasms. Clonal hematopoiesis is increas...
09/05/2026

Review series on clonal hematopoiesis: what drives its progression to myeloid neoplasms.
Clonal hematopoiesis is increasingly recognized as a precursor state with a variable risk of progression to myeloid malignancies. This review examines key biological mechanisms, risk factors, and emerging therapeutic strategies, addressing how clonal evolution may inform early detection and interventions.
https://haematologica.org/article/view/13137

Clonal hematopoiesis: from biology to clinical management.Clonal hematopoiesis (CH) as emerged as a central concept link...
07/05/2026

Clonal hematopoiesis: from biology to clinical management.
Clonal hematopoiesis (CH) as emerged as a central concept linking aging, somatic mutations, and disease risk. In this introduction to a review series on CH, Piric and Schimmer outline key themes spanning biological mechanisms to clinical implications, setting the stage for a comprehensive exploration of this rapidly evolving field. Read the CH review series in Haematologica
https://haematologica.org/article/view/14152

Landmark paper: in 2012, J.P. Patel and colleagues, publishing in The New England Journal of Medicine, reported a compre...
05/05/2026

Landmark paper: in 2012, J.P. Patel and colleagues, publishing in The New England Journal of Medicine, reported a comprehensive molecular analysis that transformed the evaluation and treatment decision-making in acute myeloid leukemia.
https://haematologica.org/article/view/14151

A dual TKI strategy in blast-phase CMLBlast-phase chronic myeloid leukemia remains a major therapeutic challenge, partic...
29/04/2026

A dual TKI strategy in blast-phase CML
Blast-phase chronic myeloid leukemia remains a major therapeutic challenge, particularly after resistance to multiple tyrosine kinase inhibitors. This case report explores the combined use of asciminib and olverembatinib, addressing an emerging strategy targeting distinct BCR-ABL1 inhibitory mechanisms in advanced-phase disease.
https://haematologica.org/article/view/13045

CAR T cells in primary CNS lymphomaTreatment options for primary central nervous system (CNS) lymphoma remain limited, p...
27/04/2026

CAR T cells in primary CNS lymphoma
Treatment options for primary central nervous system (CNS) lymphoma remain limited, particularly in relapsed or refractory disease. This case report explores the activity and CNS trafficking of tandem CD20/CD19 CAR T cells (zamtocabtagene autoleucel), addressing key questions about cellular therapy in CNS lymphoma and the potential role of dual-target CAR T strategies.
https://haematologica.org/article/view/12949

Teclistamab, a bispecific antody, was recently approved for use in relapsed/refractory multiple myeloma, following the r...
25/04/2026

Teclistamab, a bispecific antody, was recently approved for use in relapsed/refractory multiple myeloma, following the results of a pivotal phase I-II study (MajesTEC-1). Is teclistamab effective in other monoclonal gammopathies of clinical significance? Find here the case of 73-year-old man with a 20-year history of heavily treated relapsed/refractory POEMS syndrome who achieved a rapid and durable complete remission 6 months after his last injection of teclistamab.
https://haematologica.org/article/view/12152

How should we manage primary mediastinal B-cell lymphoma patients with relapsed/refractory disease after frontline DA-EP...
23/04/2026

How should we manage primary mediastinal B-cell lymphoma patients with relapsed/refractory disease after frontline DA-EPOCH-R? A retrospective review of 107 patients helps to find answers.
https://haematologica.org/article/view/12964

Neutrophils, the most abundant immune cells in human blood, play a pivotal role in host defense against invading pathoge...
21/04/2026

Neutrophils, the most abundant immune cells in human blood, play a pivotal role in host defense against invading pathogens, but are also capable of inflicting tissue damage, a common feature of diverse inflammatory pathologies. Therefore, blocking neutrophil influx has been considered an interesting therapeutic concept in diseases with overwhelming neutrophil responses. Using several in vivo and in vitro approaches a new study investigates the mode of action of ladarixin, a dual non-competitive inhibitor of chemokine receptors CXCR1 and CXCR2, in blocking neutrophil recruitment during inflammation.
https://haematologica.org/article/view/12235

The bone marrow microenvironment plays a central role in hematopoiesis and hematologic diseases. A new study investigate...
19/04/2026

The bone marrow microenvironment plays a central role in hematopoiesis and hematologic diseases. A new study investigates how HES1 regulates mesenchymal stromal cell function and inflammatory signaling, exploring a novel pathway that may shape hematopoietic homeostasis and disease biology.
https://haematologica.org/article/view/12907

About long-term outcomes with triplet therapy in FLT3-mutated acute myeloid leukemia. Triplet regimens combining hypomet...
17/04/2026

About long-term outcomes with triplet therapy in FLT3-mutated acute myeloid leukemia.
Triplet regimens combining hypomethylating agents, venetoclax, and FLT3 inhibitors are increasingly used in newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Read results of the study examining long-term outcomes and patterns of relapse with frontline triplet therapy. A key question in the evolving management of FLT3-mutated AML.
https://haematologica.org/article/view/12909

Indirizzo

Via Giuseppe Belli 4
Pavia
27100

Orario di apertura

Lunedì 09:00 - 18:00
Martedì 09:00 - 18:00
Mercoledì 09:00 - 18:00
Giovedì 09:00 - 18:00
Venerdì 09:00 - 18:00

Telefono

+39038227129

Sito Web

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Haematologica pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta Lo Studio

Invia un messaggio a Haematologica:

Scelte rapide

In evidenza

Condividi